Terumo Aortic announces PMDA approval and first commercial implant of Treo endovascular device in Japan

Treo abdominal aortic stent graft system

Following the recent approval by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) of the Treo abdominal aortic stent graft system for sale in Japan for the treatment of patients with abdominal aortic aneurysm (AAA), Terumo Aortic recently announced the first commercial implant of this device in Japan.

This first implant was undertaken by Takao Ohki, chairman of the Department of Surgery, professor and chief of the Division of Vascular Surgery, Jikei University School of Medicine, Tokyo, Japan. Ohki commented: “The procedure was very successful, the device performed well, and the patient is making a good recovery. The major concerns in endovascular surgery are stent migration and endoleaks; the Treo device provides both suprarenal and infrarenal fixation allowing for distribution of the stent graft fixation in two different anatomical levels and is expected to result in superior long-term outcomes. In addition, the Treo device is sophisticated and very user friendly with a smooth, kink-resistant detachable sheath that definitely improves the accuracy and safety of the procedure.”

According to a press release, Treo is the only device commercially available for endovascular aneurysm repair (EVAR) with dual proximal fixation and lock stent technology offering physicians the next advancement in endovascular device solutions. It is a three-piece design featuring in situ limb adjustability and provides a range of aortic device configurations to address the anatomy of each individual patient.

The press release continues: “Treo is designed for accurate, controlled and safe deployment; the exclusive proximal clasping mechanism and unique leave-behind sheath simplify the procedure as highlighted in recent clinical studies, the press release reads.”

Kotaro Yoshida, general manager at Terumo Aortic East Asia added: “This implant represents a significant milestone and demonstrates our commitment to delivering the most comprehensive portfolio in the aortic space. We look forward to continued expansion of our endovascular solutions in Japan.”

Treo received CE mark approval in 2015 and US Food and Drug Administration (FDA) approval in 2020.


Please enter your comment!
Please enter your name here